Corporate News
2024
Grant of Share Options and PDMR dealing
17 September 2021
GENinCode Plc (AIM:GENI), Oxford, UK, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today that the Remuneration Committee has recommended, and the Board has approved, to issue
options over a total of 572,000 ordinary shares of £0.01 each in the capital of the Company (“Share Options”).
The Share Options have been issued in line with the Company’s existing share option plan to Paul Foulger, a director of the Company. The Share Options have been issued in addition to the existing options over ordinary shares granted to Paul Foulger
on 15 April 2021 and combined, the number of ordinary shares held under option by Paul Foulger is 1,144,000, representing 1.19% of the existing issued ordinary share capital of the Company.
The Share Options are exercisable once the average market value of the Company’s shares for a period of 30 consecutive dealing days following the date of the issue of the Share Options first exceeds two times the exercise price of £0.44.
Contacts:
| GENinCode plc | www.genincode.com | |||
| Matthew Walls, CEO | Via Walbrook PR | |||
| Paul Foulger, CFO | ||||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | |||
| Alex Price / Ben Maddison / Richard Short | ||||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | |||
| Giles Balleny | ||||
| Dale Bellis / Michael Johnson (Sales) | ||||
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | |||
| Anna Dunphy / Paul McManus / Louis Ashe-Jepson | ||||
About GENinCode plc
GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease (“CVD”). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company’s
products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess
and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical
and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and
development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
DIRECTOR/PDMR SHAREHOLDING
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
|---|---|---|---|---|---|---|
| a) | Name | Paul Foulger | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | CFO | ||||
| b) | Initial notification/ Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | GENinCode Plc | ||||
| b) | LEI | 213800UX6TE7K65O2892 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.01p GB00BL97B504 | ||||
| b) | Nature of the transaction | Grant of conditional shares in the Company's Share Option Scheme | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
| e) | Date of the transaction | 17 September 2021 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
2023
Grant of Share Options and PDMR dealing
17 September 2021
GENinCode Plc (AIM:GENI), Oxford, UK, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today that the Remuneration Committee has recommended, and the Board has approved, to issue
options over a total of 572,000 ordinary shares of £0.01 each in the capital of the Company (“Share Options”).
The Share Options have been issued in line with the Company’s existing share option plan to Paul Foulger, a director of the Company. The Share Options have been issued in addition to the existing options over ordinary shares granted to Paul Foulger
on 15 April 2021 and combined, the number of ordinary shares held under option by Paul Foulger is 1,144,000, representing 1.19% of the existing issued ordinary share capital of the Company.
The Share Options are exercisable once the average market value of the Company’s shares for a period of 30 consecutive dealing days following the date of the issue of the Share Options first exceeds two times the exercise price of £0.44.
Contacts:
| GENinCode plc | www.genincode.com | |||
| Matthew Walls, CEO | Via Walbrook PR | |||
| Paul Foulger, CFO | ||||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | |||
| Alex Price / Ben Maddison / Richard Short | ||||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | |||
| Giles Balleny | ||||
| Dale Bellis / Michael Johnson (Sales) | ||||
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | |||
| Anna Dunphy / Paul McManus / Louis Ashe-Jepson | ||||
About GENinCode plc
GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease (“CVD”). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company’s
products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess
and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical
and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and
development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
DIRECTOR/PDMR SHAREHOLDING
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
|---|---|---|---|---|---|---|
| a) | Name | Paul Foulger | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | CFO | ||||
| b) | Initial notification/ Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | GENinCode Plc | ||||
| b) | LEI | 213800UX6TE7K65O2892 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.01p GB00BL97B504 | ||||
| b) | Nature of the transaction | Grant of conditional shares in the Company's Share Option Scheme | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
| e) | Date of the transaction | 17 September 2021 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
2022
Grant of Share Options and PDMR dealing
17 September 2021
GENinCode Plc (AIM:GENI), Oxford, UK, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today that the Remuneration Committee has recommended, and the Board has approved, to issue
options over a total of 572,000 ordinary shares of £0.01 each in the capital of the Company (“Share Options”).
The Share Options have been issued in line with the Company’s existing share option plan to Paul Foulger, a director of the Company. The Share Options have been issued in addition to the existing options over ordinary shares granted to Paul Foulger
on 15 April 2021 and combined, the number of ordinary shares held under option by Paul Foulger is 1,144,000, representing 1.19% of the existing issued ordinary share capital of the Company.
The Share Options are exercisable once the average market value of the Company’s shares for a period of 30 consecutive dealing days following the date of the issue of the Share Options first exceeds two times the exercise price of £0.44.
Contacts:
| GENinCode plc | www.genincode.com | |||
| Matthew Walls, CEO | Via Walbrook PR | |||
| Paul Foulger, CFO | ||||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | |||
| Alex Price / Ben Maddison / Richard Short | ||||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | |||
| Giles Balleny | ||||
| Dale Bellis / Michael Johnson (Sales) | ||||
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | |||
| Anna Dunphy / Paul McManus / Louis Ashe-Jepson | ||||
About GENinCode plc
GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease (“CVD”). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company’s
products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess
and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical
and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and
development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
DIRECTOR/PDMR SHAREHOLDING
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
|---|---|---|---|---|---|---|
| a) | Name | Paul Foulger | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | CFO | ||||
| b) | Initial notification/ Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | GENinCode Plc | ||||
| b) | LEI | 213800UX6TE7K65O2892 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.01p GB00BL97B504 | ||||
| b) | Nature of the transaction | Grant of conditional shares in the Company's Share Option Scheme | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
| e) | Date of the transaction | 17 September 2021 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
2021
Grant of Share Options and PDMR dealing
17 September 2021
GENinCode Plc (AIM:GENI), Oxford, UK, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today that the Remuneration Committee has recommended, and the Board has approved, to issue
options over a total of 572,000 ordinary shares of £0.01 each in the capital of the Company (“Share Options”).
The Share Options have been issued in line with the Company’s existing share option plan to Paul Foulger, a director of the Company. The Share Options have been issued in addition to the existing options over ordinary shares granted to Paul Foulger
on 15 April 2021 and combined, the number of ordinary shares held under option by Paul Foulger is 1,144,000, representing 1.19% of the existing issued ordinary share capital of the Company.
The Share Options are exercisable once the average market value of the Company’s shares for a period of 30 consecutive dealing days following the date of the issue of the Share Options first exceeds two times the exercise price of £0.44.
Contacts:
| GENinCode plc | www.genincode.com | |||
| Matthew Walls, CEO | Via Walbrook PR | |||
| Paul Foulger, CFO | ||||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | |||
| Alex Price / Ben Maddison / Richard Short | ||||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | |||
| Giles Balleny | ||||
| Dale Bellis / Michael Johnson (Sales) | ||||
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | |||
| Anna Dunphy / Paul McManus / Louis Ashe-Jepson | ||||
About GENinCode plc
GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease (“CVD”). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company’s
products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess
and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical
and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and
development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
DIRECTOR/PDMR SHAREHOLDING
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
|---|---|---|---|---|---|---|
| a) | Name | Paul Foulger | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | CFO | ||||
| b) | Initial notification/ Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | GENinCode Plc | ||||
| b) | LEI | 213800UX6TE7K65O2892 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.01p GB00BL97B504 | ||||
| b) | Nature of the transaction | Grant of conditional shares in the Company's Share Option Scheme | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
| e) | Date of the transaction | 17 September 2021 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||